Lifeward Ltd (NASDAQ: LFWD) is a medical device company that develops and sells wearable robotic exoskeletons and rehabilitation systems for individuals with mobility impairments. Revenue comes from direct product sales of the ReWalk Personal Exoskeleton, ReStore exo-suit, AlterG Anti-Gravity treadmill systems, and MyoCycle FES cycles, supplemented by related service contracts and extended warranties. The company sells primarily direct-to-consumer in the United States, through a mix of direct sales and distributors in Germany and Canada, and through distributors in other international markets. Customers include clinics, rehabilitation centers, third-party payors (private and government), professional and college sports teams, and self-pay individuals. Principal markets are the United States and Europe, with secondary sales in Asia, the Middle East, and South America. Offices are located in Yokneam, Israel; Hudson, Massachusetts; and Berlin, Germany. The company recorded a goodwill impairment charge of $2.8 million in FY2025 and an intangible asset impairment of $9.8 million in FY2024, reflecting sustained pressure on financial performance.

Revenue model

Transactional product sales of robotic exoskeletons and rehabilitation systems, supplemented by service contracts and extended warranties. Reimbursement coverage from third-party payors, including the U.S. Veterans Health Administration (VHA policy issued December 2015) and, as of February 2025, BARMER (Germany's second largest statutory health insurer, covering approximately 8.5 million lives), is a material driver of accessibility and demand.

Products and services

ReWalk Personal Exoskeleton (wearable robotic exoskeleton for spinal cord injury rehabilitation), ReStore exo-suit (soft robotic exo-suit), AlterG Anti-Gravity treadmill systems (unweighting rehabilitation systems), MyoCycle FES cycles (functional electrical stimulation cycles). Products include off-the-shelf and custom-made components produced by third-party manufacturers to company specifications.

Customers and end markets

Clinics and rehabilitation centers, professional and college sports teams, third-party payors (private insurers and government programs), commercial distributors, and self-pay individuals. Primary end markets are spinal cord injury rehabilitation, stroke rehabilitation, and sports performance recovery. The company is pursuing market expansion into stroke, multiple sclerosis, elderly assistance, and cerebral palsy indications (FY2025 10-K).

Value-chain role

Medical device designer and commercial seller. Manufacturing is outsourced to third-party component suppliers. The company manages regulatory clearance, clinical validation, sales, distribution relationships, and reimbursement coverage development.

Geographic exposure

Primary markets: United States and Europe. Secondary markets: Asia, Middle East, and South America. Direct sales in the U.S.; combination of direct and distributor in Germany and Canada; distributor-led in other markets (per FY2025 10-K).

Source: SEC 10-K, filed 2026-03-18

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies Peers: Check Cap Ltd